Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
10+ emerging markets, Japan & ANZ transition in final phase
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Receives registration of Valganciclovir powder for oral solution in Germany
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Subscribe To Our Newsletter & Stay Updated
